摘要
目的评估卡泊芬净治疗儿童血液病化疗或造血干细胞移植(HSCT)过程中真菌感染的疗效和安全性。方法 2010年4月-2013年3月我科35例血液病患儿化疗或HSCT过程中出现真菌感染,予卡泊芬净治疗,第1天予单次负荷剂量70 mg/(m2·d)(实际剂量不超过70 mg/d),随后维持剂量50 mg/(m2·d)(实际剂量不超过70 mg/d),回顾性分析其疗效和安全性。结果卡泊芬净治疗35例儿童血液病化疗或HSCT过程真菌感染总有效率为71%(25/35),毒副作用发生率为3%(1/35)。其毒副作用表现为可逆性肝功能损害,停药后好转。结论卡泊芬净有效率高,安全性好,可以作为儿童血液病化疗或HSCT过程中真菌感染治疗的选择。
Objective To evaluate the efficacy and safety of caspofungin therapy in fungal infection of pediatric hematological patients accepting chemotherapy or hematopoietic stem cell transplantation, netbodsFrom April 2010 to March 2013, there were thirty-five pediatric hematological patients with fungal infection, they were treated with caspofungin in first dose of 70 rag/（ m2 · d ）, and followed by maintenance dose of 50 rag/（ m2 · d ） , of which the clinical efficacy and side effects were analyzed retrospectively. Results The overall clinical efficacy rate of caspofungin was 71% and the incidence of side effects was 3%. The side effect was hepatic dysfunction, which is reversible. Conclusions Caspofungin therapy provides high efficacy and safety in these thirty-five pediatric patients. It may be a good choice as a therapy in fungal infection for the pediatric hematological patients accepting chemotherapy or hematopoietic stem cell transplantation.
出处
《中国小儿血液与肿瘤杂志》
CAS
2014年第2期94-98,共5页
Journal of China Pediatric Blood and Cancer
关键词
卡泊芬净
血液病
造血干细胞移植
儿童
真菌感染
Caspofungin
Hematopathy
Hematopoietic stem cell transplantation
Children
Fungal infection
